In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, were welcomed to MHE's first DC Roundtable podcast episode for a discussion on healthcare policy issues.
Murray discussed the impact of Medicaid redetermination on their members, noting significant losses and ongoing challenges.
She emphasized the importance of addressing rate setting and policy flexibility to ensure continuity of care for Medicaid beneficiaries.
Connolly echoed Murray's concerns, emphasizing efforts to ensure individuals rolling off Medicaid maintain insurance coverage, though she expressed further concerns about large for-profit nationals overshadowing nonprofit local plans in Medicaid bidding processes.
Both Murray and Connolly acknowledged the ACA's success in expanding healthcare access but highlighted ongoing affordability challenges and the need for enhanced subsidies.
Regarding partisan divides on the ACA, they stressed the need to separate political "rhetoric" from healthcare benefits.
Despite negative public views on the ACA, many still rely on its provisions for coverage, highlighting the disconnect between public opinion and healthcare needs.
Murray emphasized the need for regulatory changes to strengthen the ACA, stating, "There's still places that the law needs tightening... that's one we'd like to see a permanent codification of the regulation, but even just to get the regulation change from what the previous administration did would be good."
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
April 27th 2024This week, the FDA has approved several products, including Beqvez, the second gene therapy hemophilia B; Ojemda for children with brain tumors; an additional indication for Lutathera for adolescents with neuroendocrine tumors; and a bladder cancer immunotherapy. The agency has also issued a complete response letter for pz-cel to treat epidermolysis bullosa.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen